Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation.

Abstract

Post-transplant lymphoproliferative disorder (PTLD) describes a spectrum of conditions with highest incidence in the first year post-solid organ transplant in pediatric patients. Central nervous system (CNS) involvement with PTLD carries high mortality risk with no consensus on optimal therapeutic regimen. We present the case of a 7-year old heart transplant patient diagnosed with widespread monomorphic, CD20+, Epstein-Barr virus-positive PTLD, including CNS involvement. In addition to immunosuppression reduction and rituximab, she was treated with multiagent systemic and intrathecal chemotherapy. She achieved a prompt and complete clinical and radiologic remission, which has been sustained for over 46 months since diagnosis.

DOI: 10.1002/pbc.25129

Cite this paper

@article{Mahapatra2014SuccessfulTO, title={Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation.}, author={Sidharth Mahapatra and Clifford C Chin and Andrei H. Iagaru and Amy E Heerema-McKenney and Clare J. Twist}, journal={Pediatric blood & cancer}, year={2014}, volume={61 11}, pages={2107-9} }